Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9918419,response rate,"Four complete and 11 partial responders were observed among 66 evaluable patients, yielding a response rate of 22.7% (95% confidence interval 12.9 32.5%).","Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918419/),%,22.7,1592,DB00851,Dacarbazine
,9918419,survival time,The median survival time was 6.4 months (range 0.1-52+ months).,"Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918419/),month,6.4,1593,DB00851,Dacarbazine
,13680158,CL/F,"The population mean (inter- and intrapatient variability expressed as %CV) for the pharmacokinetic parameters (based on the training set) were as follows: TMZ CL/F 5.4 l/h (53.4, 17.5), Vc/F 14.0 l (48.5, 39.2), C(max) 9.1 mg/l (20.8, 29.1), and MTIC AUC 1.0 microg/ml.h (13.9, 30.0).",Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680158/),[l] / [h],5.4,2806,DB00851,Dacarbazine
,13680158,Vc/F,"The population mean (inter- and intrapatient variability expressed as %CV) for the pharmacokinetic parameters (based on the training set) were as follows: TMZ CL/F 5.4 l/h (53.4, 17.5), Vc/F 14.0 l (48.5, 39.2), C(max) 9.1 mg/l (20.8, 29.1), and MTIC AUC 1.0 microg/ml.h (13.9, 30.0).",Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680158/),l,14.0,2807,DB00851,Dacarbazine
,13680158,C(max),"The population mean (inter- and intrapatient variability expressed as %CV) for the pharmacokinetic parameters (based on the training set) were as follows: TMZ CL/F 5.4 l/h (53.4, 17.5), Vc/F 14.0 l (48.5, 39.2), C(max) 9.1 mg/l (20.8, 29.1), and MTIC AUC 1.0 microg/ml.h (13.9, 30.0).",Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680158/),[mg] / [l],9.1,2808,DB00851,Dacarbazine
,13680158,AUC,"The population mean (inter- and intrapatient variability expressed as %CV) for the pharmacokinetic parameters (based on the training set) were as follows: TMZ CL/F 5.4 l/h (53.4, 17.5), Vc/F 14.0 l (48.5, 39.2), C(max) 9.1 mg/l (20.8, 29.1), and MTIC AUC 1.0 microg/ml.h (13.9, 30.0).",Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680158/),[μg] / [h·ml],1.0,2809,DB00851,Dacarbazine
,10430061,time to maximum plasma concentration (Tmax),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.1,2959,DB00851,Dacarbazine
,10430061,time to maximum plasma concentration (Tmax),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.7,2960,DB00851,Dacarbazine
,10430061,elimination half-life (t1/2),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.74,2961,DB00851,Dacarbazine
,10430061,elimination half-life (t1/2),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,2.35,2962,DB00851,Dacarbazine
,10430061,clearance (Cl(s)/F),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),[ml] / [m2·min],115,2963,DB00851,Dacarbazine
,10430061,clearance (Cl(s)/F),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),[ml] / [m2·min],141,2964,DB00851,Dacarbazine
,1933662,bioavailability,The bioavailability of the drug over 24 hours was 107 micrograms/h.,Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933662/),[μg] / [h],107,4496,DB00851,Dacarbazine
,19521262,survival,The median survival was 14.8 months.,Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19521262/),month,14.8,5673,DB00851,Dacarbazine
,30357450,peak plasma,"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],3-4,7606,DB00851,Dacarbazine
,30357450,brain tissue letrozole,"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],3-4,7607,DB00851,Dacarbazine
,30357450,concentrations (Cmax),"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],0.8-0.9,7608,DB00851,Dacarbazine
,30357450,elimination half-life,The elimination half-life was 2.6 h with minimal accumulation following multiple dosing.,Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),h,2.6,7609,DB00851,Dacarbazine
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],14.7,7610,DB00851,Dacarbazine
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],4.6,7611,DB00851,Dacarbazine
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],12.6,7612,DB00851,Dacarbazine
,9815639,Peak plasma concentrations,Peak plasma concentrations of 0.07-0.61 microgram/ml MTIC were observed approximately 1 h after a p.o. dose of TMZ.,Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815639/),[μg] / [ml],0.07-0.61,8066,DB00851,Dacarbazine
,9815639,t1/2,"Appearance and disappearance (t1/2, 88 min) of the reactive metabolite paralleled the appearance and disappearance of TMZ in plasma.",Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815639/),min,88,8067,DB00851,Dacarbazine
> or =,9448080,recovery,The recovery of MTIC and internal standard was > or = 86.7%.,"High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),%,86.7,8089,DB00851,Dacarbazine
,9448080,maximum plasma concentration (Cmax),The mean maximum plasma concentration (Cmax) was 211 ng/ml which was observed at a mean Tmax of 1.88 h post dose.,"High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),[ng] / [ml],211,8090,DB00851,Dacarbazine
,9448080,Tmax,The mean maximum plasma concentration (Cmax) was 211 ng/ml which was observed at a mean Tmax of 1.88 h post dose.,"High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),h,1.88,8091,DB00851,Dacarbazine
,9448080,apparent,MTIC disappeared rapidly from plasma with an apparent in vivo half-life (t1/2) of 1.9 h similar to that of temozolomide.,"High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),h,1.9,8092,DB00851,Dacarbazine
,9448080,half-life (t1/2),MTIC disappeared rapidly from plasma with an apparent in vivo half-life (t1/2) of 1.9 h similar to that of temozolomide.,"High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),h,1.9,8093,DB00851,Dacarbazine
,9448080,t1/2,"Following in vitro incubation of MTIC in human plasma at 25 degrees C, MTIC disappearance was bioexponential with estimated t1/2 values of 25 and 60 min for the first and second phases, respectively.","High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),min,25,8094,DB00851,Dacarbazine
,9448080,t1/2,"Following in vitro incubation of MTIC in human plasma at 25 degrees C, MTIC disappearance was bioexponential with estimated t1/2 values of 25 and 60 min for the first and second phases, respectively.","High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),min,60,8095,DB00851,Dacarbazine
,9448080,elimination t1/2,"Therefore, the elimination t1/2 of MTIC in human in vivo (1.9 h) was controlled by the rate of its formation from temozolomide.","High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448080/),h,1.9,8096,DB00851,Dacarbazine
,2337862,duration of response,The median duration of response was 4.7 months.,A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337862/),month,4.7,9162,DB00851,Dacarbazine
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,0.75,12948,DB00851,Dacarbazine
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,1.5,12949,DB00851,Dacarbazine
,24786603,progression-free survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,7.9,12950,DB00851,Dacarbazine
,24786603,overall survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,17.8,12951,DB00851,Dacarbazine
,24093213,MTD,The MTD of cyclical oral TMZ was 100 mg/m² on days 1-7 and 15-21 when combined with weekly subcutaneous PEG-IFNα-2b at 1.5 mcg/kg/week on 28 days cycles.,"A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24093213/),[mg] / [m²],100,15027,DB00851,Dacarbazine
,23989947,overall response rate,The overall response rate with plitidepsin/DTIC was 21.4%; all responders had normal serum lactate dehydrogenase (LDH) levels and performance status ≤ 1 at baseline.,Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23989947/),%,21.4,21715,DB00851,Dacarbazine
,23989947,progression-free survival (PFS),"Median progression-free survival (PFS) with plitidepsin/DTIC was 3.3 months in all patients, and 4.3 months in those with baseline normal LDH.",Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23989947/),month,3.3,21716,DB00851,Dacarbazine
,23989947,progression-free survival (PFS),"Median progression-free survival (PFS) with plitidepsin/DTIC was 3.3 months in all patients, and 4.3 months in those with baseline normal LDH.",Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23989947/),month,4.3,21717,DB00851,Dacarbazine
,23989947,PFS,No responses occurred with single-agent plitidepsin and median PFS was 1.5 months.,Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23989947/),month,1.5,21718,DB00851,Dacarbazine
,9766665,overall response rate,"The overall response rate for this prolonged schedule was 33% (objective response, 7 of 24 patients; partial response, 1 of 24 patients); also, 6 of 17 glioma patients maintained SD.",Phase I trial of temozolomide using an extended continuous oral schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),%,33,21933,DB00851,Dacarbazine
,9766665,elimination half-life,Elimination in plasma was best described by a monoexponential equation with an elimination half-life of 96 +/- 16 min.,Phase I trial of temozolomide using an extended continuous oral schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),min,96,21934,DB00851,Dacarbazine
,9766665,maximum tolerated dose,"Toxicity was greatest in higher dose cohorts, with a resultant maximum tolerated dose of 85 mg/m2/day, whereas lower dose cohorts tolerated the schedule well.",Phase I trial of temozolomide using an extended continuous oral schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),[mg] / [d·m2],85,21935,DB00851,Dacarbazine
,9766665,overall response rate,"The overall response rate was 33% (glioma patients, 41% and a further 25% SD).",Phase I trial of temozolomide using an extended continuous oral schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),%,33,21936,DB00851,Dacarbazine
,9766665,overall response rate,"The overall response rate was 33% (glioma patients, 41% and a further 25% SD).",Phase I trial of temozolomide using an extended continuous oral schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),%,41,21937,DB00851,Dacarbazine
,9766665,overall response rate,"The overall response rate was 33% (glioma patients, 41% and a further 25% SD).",Phase I trial of temozolomide using an extended continuous oral schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766665/),%,25,21938,DB00851,Dacarbazine
,17634557,area under the drug concentration-time curve ratios,"The developed physiologically based pharmacokinetic model afforded a mechanistic and accurate prediction of temozolomide brain disposition in rats, which through model scale-up procedures accurately predicted the CSF/plasma area under the drug concentration-time curve ratios of 0.2 reported in patients.",Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634557/),,0.2,22559,DB00851,Dacarbazine
,28039367,progression-free survival,The median duration of progression-free survival was 6.1 months; median overall survival has not been reached.,Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039367/),month,6.1,22992,DB00851,Dacarbazine
,19125222,bioavailability,"Although the bioavailability of temozolomide is approximately 100%, pathology or anatomical changes of the gastrointestinal tract may adversely affect absorption, and consequently therapeutic response.",Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19125222/),%,100,25779,DB00851,Dacarbazine
,19861433,areas under the concentration-time curve (AUC),"The mean temozolomide areas under the concentration-time curve (AUC) in plasma and brain interstitium were 17.1 and 2.7 microg/mL x hour, with an average brain interstitium/plasma AUC ratio of 17.8%.",The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861433/),[μg] / [h·ml],17.1,29311,DB00851,Dacarbazine
,19861433,areas under the concentration-time curve (AUC),"The mean temozolomide areas under the concentration-time curve (AUC) in plasma and brain interstitium were 17.1 and 2.7 microg/mL x hour, with an average brain interstitium/plasma AUC ratio of 17.8%.",The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861433/),[μg] / [h·ml],2.7,29312,DB00851,Dacarbazine
,19861433,AUC ratio,"The mean temozolomide areas under the concentration-time curve (AUC) in plasma and brain interstitium were 17.1 and 2.7 microg/mL x hour, with an average brain interstitium/plasma AUC ratio of 17.8%.",The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861433/),%,17.8,29313,DB00851,Dacarbazine
,19861433,peak temozolomide concentration,"The mean peak temozolomide concentration in the brain was 0.6 +/- 0.3 microg/mL, and the mean time to reach peak level in brain was 2.0 +/- 0.8 hours.",The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861433/),[μg] / [ml],0.6,29314,DB00851,Dacarbazine
,19861433,time to reach peak level,"The mean peak temozolomide concentration in the brain was 0.6 +/- 0.3 microg/mL, and the mean time to reach peak level in brain was 2.0 +/- 0.8 hours.",The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861433/),h,2.0,29315,DB00851,Dacarbazine
,11505406,overall response rate,"The overall response rate in the HDT group was 50% (95% confidence interval, 33.2%-66.8%), with a complete response rate of 6% and a median survival of 9.5 months.",High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505406/),%,50,35237,DB00851,Dacarbazine
,11505406,complete response rate,"The overall response rate in the HDT group was 50% (95% confidence interval, 33.2%-66.8%), with a complete response rate of 6% and a median survival of 9.5 months.",High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505406/),%,6,35238,DB00851,Dacarbazine
,26626489,concentrations,"Brain temozolomide concentrations were significantly higher at 120 min when it was given with regadenoson versus alone (8.1 ± 2.7 and 5.1 ± 3.5 µg/g, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),µ,8.1,40865,DB00851,Dacarbazine
,26626489,concentrations,"Brain temozolomide concentrations were significantly higher at 120 min when it was given with regadenoson versus alone (8.1 ± 2.7 and 5.1 ± 3.5 µg/g, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),µ,5.1,40866,DB00851,Dacarbazine
,26626489,brain:plasma ratios,"A similar trend was noted in brain:plasma ratios (0.45 ± 0.08 and 0.29 ± 0.09, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),,0.45,40867,DB00851,Dacarbazine
,26626489,brain:plasma ratios,"A similar trend was noted in brain:plasma ratios (0.45 ± 0.08 and 0.29 ± 0.09, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),,0.29,40868,DB00851,Dacarbazine
,33785481,MTD,MTD of zotiraciclib was 250 mg in both arms and thus selected for the cohort expansion.,Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33785481/),mg,250,47223,DB00851,Dacarbazine
,20564083,MTD,The MTD of imexon with dacarbazine was 1000 mg/m2.,A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),[mg] / [m2],1000,52934,DB00851,Dacarbazine
,20564083,Partial response,"Partial response and stable disease rates were 5.9% and 25% for all subjects and 2% and 30% for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),%,5.9,52935,DB00851,Dacarbazine
,20564083,stable disease rates,"Partial response and stable disease rates were 5.9% and 25% for all subjects and 2% and 30% for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),%,25,52936,DB00851,Dacarbazine
,20564083,stable disease rates,"Partial response and stable disease rates were 5.9% and 25% for all subjects and 2% and 30% for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),%,2,52937,DB00851,Dacarbazine
,20564083,stable disease rates,"Partial response and stable disease rates were 5.9% and 25% for all subjects and 2% and 30% for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),%,30,52938,DB00851,Dacarbazine
,20564083,progression-free,"Median progression-free and overall survival of all patients were 2.0 and 11.7 months and 2 and 7.5 months for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),month,2.0,52939,DB00851,Dacarbazine
,20564083,overall survival,"Median progression-free and overall survival of all patients were 2.0 and 11.7 months and 2 and 7.5 months for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),month,11.7,52940,DB00851,Dacarbazine
,20564083,overall survival,"Median progression-free and overall survival of all patients were 2.0 and 11.7 months and 2 and 7.5 months for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),month,2,52941,DB00851,Dacarbazine
,20564083,overall survival,"Median progression-free and overall survival of all patients were 2.0 and 11.7 months and 2 and 7.5 months for the phase 2 patients, respectively.",A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),month,7.5,52942,DB00851,Dacarbazine
>,20564083,Overall survival,Overall survival of the 31 patients with normal lactate dehydrogenase levels was >22.5 months.,A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564083/),month,22.5,52943,DB00851,Dacarbazine
,29332604,plasma AUC,The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],16.4,60224,DB00851,Dacarbazine
,29332604,plasma AUC,The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],16.6,60225,DB00851,Dacarbazine
,29332604,AUC,The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],2.9,60226,DB00851,Dacarbazine
,29332604,AUC,The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],3.0,60227,DB00851,Dacarbazine
,29332604,brain:plasma AUC ratio,The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),%,18.0,60228,DB00851,Dacarbazine
,29332604,brain:plasma AUC ratio,The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),%,19.1,60229,DB00851,Dacarbazine
,18056194,maximum tolerated dose,The maximum tolerated dose for irinotecan was determined to be 500 mg/m(2).,Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18056194/),mg,500,61543,DB00851,Dacarbazine
,32009149,overall survival rates,"The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively.",A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32009149/),%,5.3,61708,DB00851,Dacarbazine
,29184162,particle size,The particle size of DZNP and DZNC was 16.3 ± 8.1 nm and 16.9 ± 7.8 nm respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),nm,16.3,63778,DB00851,Dacarbazine
,29184162,particle size,The particle size of DZNP and DZNC was 16.3 ± 8.1 nm and 16.9 ± 7.8 nm respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),nm,16.9,63779,DB00851,Dacarbazine
,29184162,pH value,pH value and spreadability of nanoparticle cream were found to be 6.7 ± 0.14 g cm/sec and 55.23 ± 3.13 g cm/sec respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),[cm·g] / [s],6.7,63780,DB00851,Dacarbazine
,29184162,spreadability,pH value and spreadability of nanoparticle cream were found to be 6.7 ± 0.14 g cm/sec and 55.23 ± 3.13 g cm/sec respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),[cm·g] / [s],55.23,63781,DB00851,Dacarbazine
,29184162,Nanoenc,Nanoencapsulation efficiency and Drug loading capacity were 67.4 ± 3.5% and 6.73 mg/10 mg respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),%,67.4,63782,DB00851,Dacarbazine
,29184162,Drug loading capacity,Nanoencapsulation efficiency and Drug loading capacity were 67.4 ± 3.5% and 6.73 mg/10 mg respectively.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),[mg] / [10·mg],6.73,63783,DB00851,Dacarbazine
,29184162,IC50,IC50 of dacarbazine nanoparticle was 0.19 mg/ml while it was 0.63 mg/ml for nanoparticle cream.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),[mg] / [ml],0.19,63784,DB00851,Dacarbazine
,29184162,IC50,IC50 of dacarbazine nanoparticle was 0.19 mg/ml while it was 0.63 mg/ml for nanoparticle cream.,Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29184162/),[mg] / [ml],0.63,63785,DB00851,Dacarbazine
,16899365,MTD,MTD in both strata was 85 mg/m2.,"Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16899365/),[mg] / [m2],85,65913,DB00851,Dacarbazine
,18359865,MTD,"The MTD of imatinib for patients concurrently receiving or not receiving EIAEDs was 1,000 mg.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),mg,"1,000",67011,DB00851,Dacarbazine
,18359865,progression-free,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,41.7,67012,DB00851,Dacarbazine
,18359865,overall survival times,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,56.1,67013,DB00851,Dacarbazine
,9788568,clearance,"The clearance after i.v. administration was 220 +/- 48 and 241 +/- 39 ml/min on days 1 and 2, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[ml] / [min],220,68637,DB00851,Dacarbazine
,9788568,clearance,"The clearance after i.v. administration was 220 +/- 48 and 241 +/- 39 ml/min on days 1 and 2, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[ml] / [min],241,68638,DB00851,Dacarbazine
,9788568,apparent clearance,"The apparent clearance after p.o. and h.i.a. administration was 290 +/- 86 and 344 +/- 77 ml/min, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[ml] / [min],290,68639,DB00851,Dacarbazine
,9788568,apparent clearance,"The apparent clearance after p.o. and h.i.a. administration was 290 +/- 86 and 344 +/- 77 ml/min, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[ml] / [min],344,68640,DB00851,Dacarbazine
,9788568,volume of distribution,"The volume of distribution of TMZ after i.v., p.o., and h.i.a. administration was 0.4, 0.6, and 0.6 l/kg on day 1 and 0.5, 0.5, and 0.6 l/kg on day 2, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[l] / [kg],0.4,68641,DB00851,Dacarbazine
,9788568,volume of distribution,"The volume of distribution of TMZ after i.v., p.o., and h.i.a. administration was 0.4, 0.6, and 0.6 l/kg on day 1 and 0.5, 0.5, and 0.6 l/kg on day 2, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[l] / [kg],0.6,68642,DB00851,Dacarbazine
,9788568,volume of distribution,"The volume of distribution of TMZ after i.v., p.o., and h.i.a. administration was 0.4, 0.6, and 0.6 l/kg on day 1 and 0.5, 0.5, and 0.6 l/kg on day 2, respectively.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),[l] / [kg],0.5,68643,DB00851,Dacarbazine
,9788568,absolute bioavailability,"The absolute bioavailability of TMZ was 0.96 +/- 0.1, regardless of the sequence of the i.v.-p.o. or p.o.-i.v. administration, confirming that TMZ is not subject to a marked first-pass effect.","Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788568/),,0.96,68644,DB00851,Dacarbazine
,23833564,AUC,Patients in the CP group received paclitaxel 175 mg/m(2) IV and carboplatin [AUC=6] IV every 3 weeks.,Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),,6,71366,DB00851,Dacarbazine
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,29.4,71367,DB00851,Dacarbazine
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,27.8,71368,DB00851,Dacarbazine
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,11.1,71369,DB00851,Dacarbazine
,8431368,t1/2,The mean t1/2 of the parent drug was 178 min.,Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431368/),min,178,73193,DB00851,Dacarbazine
,8431368,Area under the concentration x time curve (AUC),"Area under the concentration x time curve (AUC) at the highest dose for the parent drug and the monomethyl metabolite were 2,350 and 9 mM x minutes, respectively.",Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431368/),mM·min,"2,350",73194,DB00851,Dacarbazine
,8431368,Area under the concentration x time curve (AUC),"Area under the concentration x time curve (AUC) at the highest dose for the parent drug and the monomethyl metabolite were 2,350 and 9 mM x minutes, respectively.",Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431368/),mM·min,9,73195,DB00851,Dacarbazine
,12750260,systemic clearance,"There was rapid systemic clearance of both radiolabelled forms of [(11)C]temozolomide over 90 min (0.2 liter/min/m(2)), with [(11)C]CO(2) being the primary elimination product.",Metabolic activation of temozolomide measured in vivo using positron emission tomography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12750260/),[l·min] / [m(2],0.2,74373,DB00851,Dacarbazine
,20439646,PFS,"Median PFS was 8 months (95% CI, 6.0 to 10.7 months).",Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),,8,80026,DB00851,Dacarbazine
,20439646,OS,"Median OS was 16.1 months (95% CI, 13.1 to 23.2 months).",Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,16.1,80027,DB00851,Dacarbazine
,20439646,PFS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,13,80028,DB00851,Dacarbazine
,20439646,PFS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,23,80029,DB00851,Dacarbazine
,20439646,PFS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,3,80030,DB00851,Dacarbazine
,20439646,OS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,23,80031,DB00851,Dacarbazine
,20439646,OS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,3,80032,DB00851,Dacarbazine
,20439646,OS,PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months).,Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439646/),month,13,80033,DB00851,Dacarbazine
,18475294,time to progression,Median time to progression was 50 days.,A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475294/),d,50,80502,DB00851,Dacarbazine
,23423489,response rate,"The response rate was 17.4 %, median time to progression 3.5 months, median overall survival 9.9 months, and 36 % of patients were progression-free at 6 months.","A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23423489/),%,17.4,81532,DB00851,Dacarbazine
,23423489,time to progression,"The response rate was 17.4 %, median time to progression 3.5 months, median overall survival 9.9 months, and 36 % of patients were progression-free at 6 months.","A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23423489/),month,3.5,81533,DB00851,Dacarbazine
,23423489,overall survival,"The response rate was 17.4 %, median time to progression 3.5 months, median overall survival 9.9 months, and 36 % of patients were progression-free at 6 months.","A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23423489/),month,9.9,81534,DB00851,Dacarbazine
,21600759,OS,"Median OS was 9.1 months in the temozolomide arm and 9.4 months in the dacarbazine arm, with a hazard ratio (HR) of 1.00 (95%confidence interval [CI]: 0.86, 1.17; P=0.99).","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),month,9.1,88112,DB00851,Dacarbazine
,21600759,OS,"Median OS was 9.1 months in the temozolomide arm and 9.4 months in the dacarbazine arm, with a hazard ratio (HR) of 1.00 (95%confidence interval [CI]: 0.86, 1.17; P=0.99).","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),month,9.,88113,DB00851,Dacarbazine
,21600759,progression-free survival (PFS),"Median progression-free survival (PFS) was 2.3 months in the temozolomide arm and 2.2 months in the dacarbazine arm, with a HR of 0.92 (95%CI: 0.80, 1.06; P=0.27).","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),month,2.3,88114,DB00851,Dacarbazine
,21600759,progression-free survival (PFS),"Median progression-free survival (PFS) was 2.3 months in the temozolomide arm and 2.2 months in the dacarbazine arm, with a HR of 0.92 (95%CI: 0.80, 1.06; P=0.27).","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),month,2.2,88115,DB00851,Dacarbazine
,21600759,overall response rate,"In patients with measurable disease, overall response rate was higher in the temozolomide arm than in the dacarbazine arm (14.5% versus 9.8%, respectively), but the median duration of response was longer for dacarbazine.","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),%,14.5,88116,DB00851,Dacarbazine
,21600759,overall response rate,"In patients with measurable disease, overall response rate was higher in the temozolomide arm than in the dacarbazine arm (14.5% versus 9.8%, respectively), but the median duration of response was longer for dacarbazine.","Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600759/),%,9.8,88117,DB00851,Dacarbazine
,10037179,half-life,"Maximum TMZ plasma concentrations were achieved between 0.33 to 2 h (mean, 1.2 h), and half-life, apparent volume of distribution, and oral clearance values averaged 1.9 h, 17 liters/m2, and 104 ml/min/m2, respectively.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),h,1.9,92680,DB00851,Dacarbazine
,10037179,apparent volume of distribution,"Maximum TMZ plasma concentrations were achieved between 0.33 to 2 h (mean, 1.2 h), and half-life, apparent volume of distribution, and oral clearance values averaged 1.9 h, 17 liters/m2, and 104 ml/min/m2, respectively.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),[l] / [m2],17,92681,DB00851,Dacarbazine
,10037179,oral clearance,"Maximum TMZ plasma concentrations were achieved between 0.33 to 2 h (mean, 1.2 h), and half-life, apparent volume of distribution, and oral clearance values averaged 1.9 h, 17 liters/m2, and 104 ml/min/m2, respectively.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),[ml] / [m2·min],104,92682,DB00851,Dacarbazine
,10037179,systemic clearance,"MTIC systemic clearance was estimated to be 5384 ml/min/m2, and the half-life was calculated to be 2.5 min.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),[ml] / [m2·min],5384,92683,DB00851,Dacarbazine
,10037179,half-life,"MTIC systemic clearance was estimated to be 5384 ml/min/m2, and the half-life was calculated to be 2.5 min.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),min,2.5,92684,DB00851,Dacarbazine
,10037179,recovered radioactive,"The recovered radioactive dose (39%) was principally eliminated in the urine (38%), and a small amount (0.8%) was excreted in the feces.","Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10037179/),%,39,92685,DB00851,Dacarbazine
,23436249,limit of,The method has a limit of quantification of 50 ng/mL for temozolomide in plasma and 125 ng/g in brain.,Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436249/),[ng] / [ml],50,95030,DB00851,Dacarbazine
,15645126,oral,Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml).,Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645126/),[ng] / [ml],1041,96721,DB00851,Dacarbazine
,15645126,plasma Cmax,Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml).,Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645126/),[ng] / [ml],1041,96722,DB00851,Dacarbazine
,15645126,brain/plasma ratios,"Moreover, the brain levels and brain/plasma ratios of GPI 15427 (3.37 at 0.5 h and 3.19 at 1 h) indicated that the compound readily penetrates the blood-brain barrier.",Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645126/),,3,96723,DB00851,Dacarbazine
,17929115,time-to-maximum plasma concentration (tmax),The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h.,Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17929115/),h,1,97882,DB00851,Dacarbazine
,17929115,elimination half-life of terminal excretion phase (t 1/2lambda z),The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h.,Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17929115/),h,2,97883,DB00851,Dacarbazine
,26193943,polydispersity index (PI),They were found to be relatively uniform in size of 156.70 ± 11.40 nm with a narrow polydispersity index (PI) of 0.29 ± 0.04.,"Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193943/),,0.29,102748,DB00851,Dacarbazine
,26193943,drug,"The average drug entrapment efficiency and loading capacity were 35.45 ± 1.48% and 2.81 ± 0.20%, respectively.","Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193943/),%,35.45,102749,DB00851,Dacarbazine
,26193943,entrapment efficiency,"The average drug entrapment efficiency and loading capacity were 35.45 ± 1.48% and 2.81 ± 0.20%, respectively.","Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193943/),%,35.45,102750,DB00851,Dacarbazine
,26193943,loading capacity,"The average drug entrapment efficiency and loading capacity were 35.45 ± 1.48% and 2.81 ± 0.20%, respectively.","Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193943/),%,2.81,102751,DB00851,Dacarbazine
,25910950,OS,"Median OS was 15.9 months [95% confidence interval (CI), 11.0-22.5 months] in the RT/temozolomide arm and 16.6 months (95% CI, 14.9-20.1 months) in the vandetanib/RT/temozolomide (log-rank P = 0.75).","A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25910950/),month,15.9,107303,DB00851,Dacarbazine
,25910950,OS,"Median OS was 15.9 months [95% confidence interval (CI), 11.0-22.5 months] in the RT/temozolomide arm and 16.6 months (95% CI, 14.9-20.1 months) in the vandetanib/RT/temozolomide (log-rank P = 0.75).","A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25910950/),month,16.6,107304,DB00851,Dacarbazine
,32795876,objective response rates,The objective response rates were 10.3% (arm A) and 25% (arm B).,A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795876/),%,10.3,116842,DB00851,Dacarbazine
,32795876,objective response rates,The objective response rates were 10.3% (arm A) and 25% (arm B).,A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795876/),%,25,116843,DB00851,Dacarbazine
over,18804654,column life,"This type of column not only has an excellent column life (over 4000 injections), but also has zero carryover effect.",Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole-carboxamide in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18804654/),injections,4000,117171,DB00851,Dacarbazine
,2249333,half-lives,"No significant difference was detected in the elimination phase of DTIC when half-lives obtained before and after rIL-2 administration were compared; the mean half-lives were 0.7 and 2.8 h for the alpha- and beta-phases, respectively.",Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249333/),h,0.7,117676,DB00851,Dacarbazine
,2249333,half-lives,"No significant difference was detected in the elimination phase of DTIC when half-lives obtained before and after rIL-2 administration were compared; the mean half-lives were 0.7 and 2.8 h for the alpha- and beta-phases, respectively.",Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249333/),h,2.8,117677,DB00851,Dacarbazine
,2249333,mean residence time,The model-independent mean residence time was 3.4 h.,Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249333/),h,3.4,117678,DB00851,Dacarbazine
,2249333,alpha-,"AIC biphasic plasma elimination was also similar after rIL-2 administration, with alpha- and beta-half-lives of 0.7 and 11.4 h, respectively.",Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249333/),h,0.7,117679,DB00851,Dacarbazine
,2249333,beta-half-lives,"AIC biphasic plasma elimination was also similar after rIL-2 administration, with alpha- and beta-half-lives of 0.7 and 11.4 h, respectively.",Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2249333/),h,11.4,117680,DB00851,Dacarbazine
,20337371,K(i),Compound 22b displayed excellent potency against the PARP-1 enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.,"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20337371/),nM,1,118170,DB00851,Dacarbazine
,20337371,EC(50),Compound 22b displayed excellent potency against the PARP-1 enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.,"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20337371/),nM,1,118171,DB00851,Dacarbazine
,19174487,Cmax,"AG014699 metabolites distributed rapidly into the plasma (Cmax, 1.2-1.9 nmol/L at 30 min) and accumulated in xenograft tissues (Cmax, 1-2 micromol/L at 120 min), associated with a sustained suppression of PARP-1 enzyme activity.",Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19174487/),[nM] / [l],1.2-1.9,121726,DB00851,Dacarbazine
,19174487,Cmax,"AG014699 metabolites distributed rapidly into the plasma (Cmax, 1.2-1.9 nmol/L at 30 min) and accumulated in xenograft tissues (Cmax, 1-2 micromol/L at 120 min), associated with a sustained suppression of PARP-1 enzyme activity.",Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19174487/),[μM] / [l],1-2,121727,DB00851,Dacarbazine
,32866424,overall survival,Median overall survival was 16 months (range 2-32).,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,16,126667,DB00851,Dacarbazine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126668,DB00851,Dacarbazine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126669,DB00851,Dacarbazine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126670,DB00851,Dacarbazine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126671,DB00851,Dacarbazine
,30243056,extraction recovery,Calibration curves were linear over the range of 10-500 ng/mL with extraction recovery ranging from 77.3 to 97.3% while all validation parameters met the acceptance criteria and proved the methods' reliability.,Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243056/),%,77.3 to 97.3,128605,DB00851,Dacarbazine
,7172404,terminal half-life,"The plasma disappearance of DTIC was biphasic, with a terminal half-life of 41.4 min (range 30.3--51.6 min).",Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),min,41.4,131447,DB00851,Dacarbazine
,7172404,distribution volume,The mean distribution volume of DTIC was 0.632 liters/kg and the total clearance was 15.4 ml/kg . min (range 8.7--23.3 ml/kg . min).,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),[l] / [kg],0.632,131448,DB00851,Dacarbazine
,7172404,total clearance,The mean distribution volume of DTIC was 0.632 liters/kg and the total clearance was 15.4 ml/kg . min (range 8.7--23.3 ml/kg . min).,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),[ml] / [kg·min],15.4,131449,DB00851,Dacarbazine
,7172404,renal clearance,"The renal clearance of DTIC was 5.2--10.9 ml/kg . min, indicating that about 50% of DTIC was eliminated by extrarenal mechanisms.",Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),[ml] / [kg·min],5,131450,DB00851,Dacarbazine
,7172404,half-life,The plasma decay of AIC was mono-exponential with a half-life of 43.0--116 min.,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),min,43.0,131451,DB00851,Dacarbazine
,7172404,renal clearance,A renal clearance of 2.6--5.3 ml/kg . min was calculated for AIC.,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),[ml] / [kg·min],2.6,131452,DB00851,Dacarbazine
,7172404,urinary recovery,The urinary recovery was 46%--52% for DTIC and 9%--18% for AIC.,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),%,46,131453,DB00851,Dacarbazine
,7172404,urinary recovery,The urinary recovery was 46%--52% for DTIC and 9%--18% for AIC.,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),%,9,131454,DB00851,Dacarbazine
,7172404,plasma concentrations,The plasma concentrations of DTIC observed during 0.5--6-h infusions of DTIC (5.45--6.85 mg/kg) were 0.66--6.2 micrograms/ml.,Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172404/),,0.66,131455,DB00851,Dacarbazine
,1934251,t1/2 alpha,"The pharmacokinetics of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, dacarbazine) given at a dose of 850-1,980 mg/m2 as a 10- to 30-min infusion was studied in cancer patients, and the plasma concentration-time curves were adjusted to a two-compartment model, with a mean t1/2 alpha value of 0.17 h (range, 0.1-0.26 h) and a mean t1/2 beta value of 2 h (range, 1.5-2.7 h) being found.",Clinical pharmacokinetics of high-dose DTIC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),h,0.17,135903,DB00851,Dacarbazine
,1934251,t1/2 beta,"The pharmacokinetics of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, dacarbazine) given at a dose of 850-1,980 mg/m2 as a 10- to 30-min infusion was studied in cancer patients, and the plasma concentration-time curves were adjusted to a two-compartment model, with a mean t1/2 alpha value of 0.17 h (range, 0.1-0.26 h) and a mean t1/2 beta value of 2 h (range, 1.5-2.7 h) being found.",Clinical pharmacokinetics of high-dose DTIC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),h,2,135904,DB00851,Dacarbazine
,1934251,volume of the central compartment of (Vc),"The mean volume of the central compartment of (Vc) and the apparent volume of distribution (VB) were 0.42 1 kg-1 (range, 0.24-0.54 1 kg-1) and 1.49 1 kg-1 (range, 0.88-1.74 1 kg-1), respectively.",Clinical pharmacokinetics of high-dose DTIC. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),[1] / [kg],0.42,135905,DB00851,Dacarbazine
,1934251,apparent volume of distribution (VB),"The mean volume of the central compartment of (Vc) and the apparent volume of distribution (VB) were 0.42 1 kg-1 (range, 0.24-0.54 1 kg-1) and 1.49 1 kg-1 (range, 0.88-1.74 1 kg-1), respectively.",Clinical pharmacokinetics of high-dose DTIC. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),[1] / [kg],1.49,135906,DB00851,Dacarbazine
,1934251,total body clearance,"The mean total body clearance of DTIC was 0.58 1 kg-1 h-1 (range, 0.26-0.82 1 kg-1 h-1), and the mean renal clearance was 0.28 1 kg-1 h-1 (range, 0.17-0.49 1 kg-1 h-1).",Clinical pharmacokinetics of high-dose DTIC. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),[1] / [h·kg],0.58,135907,DB00851,Dacarbazine
,1934251,renal clearance,"The mean total body clearance of DTIC was 0.58 1 kg-1 h-1 (range, 0.26-0.82 1 kg-1 h-1), and the mean renal clearance was 0.28 1 kg-1 h-1 (range, 0.17-0.49 1 kg-1 h-1).",Clinical pharmacokinetics of high-dose DTIC. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),[1] / [h·kg],0.28,135908,DB00851,Dacarbazine
,1934251,t1/2,"The metabolite aminoimidazole carboxamide (AICA) was detectable in plasma from the start of DTIC infusion, and its concentration-time curve showed a monophasic decay, exhibiting a mean t1/2 value of 3.25 h (range, 1.77-5.82 h).",Clinical pharmacokinetics of high-dose DTIC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),h,3.25,135909,DB00851,Dacarbazine
,1934251,renal clearance,"Mean AICA renal clearance was 0.15 1 kg-1 h-1 (range, 0.05-0.32 1 kg-1 h-1).",Clinical pharmacokinetics of high-dose DTIC. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934251/),[1] / [h·kg],0.15,135910,DB00851,Dacarbazine
,11199225,degradation t1/2,"Temozolomide was unstable at 37 degrees C in human plasma with a degradation t1/2 of 15 min; however, it was stable at 4 degrees C for at least 30 min.",High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199225/),min,15,142513,DB00851,Dacarbazine
,22644796,area under the concentration-time curve (AUC(0-∞)),Tumor TMZ mean area under the concentration-time curve (AUC(0-∞)) was 3.35 μg h/mL pre-BEV.,The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644796/),[h·μg] / [ml],3.35,142883,DB00851,Dacarbazine
,22644796,AUC(0-∞),"Post-BEV, tumor mean TMZ AUC(0-∞) was 3.98 μg h/mL.",The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644796/),[h·μg] / [ml],3.98,142884,DB00851,Dacarbazine
,22644796,AUC(0-∞),"In non-tumor brain, mean TMZ AUC(0-∞) pre-BEV was 3.22 μg h/mL and post-BEV was 3.34 μg h/mL.",The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644796/),[h·μg] / [ml],3.22,142885,DB00851,Dacarbazine
,22644796,AUC(0-∞),"In non-tumor brain, mean TMZ AUC(0-∞) pre-BEV was 3.22 μg h/mL and post-BEV was 3.34 μg h/mL.",The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22644796/),[h·μg] / [ml],3.34,142886,DB00851,Dacarbazine
,10561328,half-life,"TMZ was absorbed rapidly with maximum concentrations achieved in 0.90 hours, on average, and elimination was rapid, with a half-life and systemic clearance rate (Cl(S/F)) averaging 1.8 hours and 115 mL/min/m(2), respectively.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),h,1.8,143613,DB00851,Dacarbazine
,10561328,systemic clearance rate (Cl(S/F)),"TMZ was absorbed rapidly with maximum concentrations achieved in 0.90 hours, on average, and elimination was rapid, with a half-life and systemic clearance rate (Cl(S/F)) averaging 1.8 hours and 115 mL/min/m(2), respectively.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),[min·ml] / [m(2],115,143614,DB00851,Dacarbazine
,10561328,maximum drug concentration( ),"Patients who experienced DLT had significantly higher maximum drug concentration( )(median 16 v 9.5 microg/mL, P =. 0084) and area under the concentration-time curve (median 36 v 23 microg-h/mL, P =.0019) values on day 5.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),[μg] / [ml],16,143615,DB00851,Dacarbazine
,10561328,maximum drug concentration( ),"Patients who experienced DLT had significantly higher maximum drug concentration( )(median 16 v 9.5 microg/mL, P =. 0084) and area under the concentration-time curve (median 36 v 23 microg-h/mL, P =.0019) values on day 5.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),[μg] / [ml],9.5,143616,DB00851,Dacarbazine
,10561328,area under the concentration-time curve,"Patients who experienced DLT had significantly higher maximum drug concentration( )(median 16 v 9.5 microg/mL, P =. 0084) and area under the concentration-time curve (median 36 v 23 microg-h/mL, P =.0019) values on day 5.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),[μg-h] / [ml],36,143617,DB00851,Dacarbazine
,10561328,area under the concentration-time curve,"Patients who experienced DLT had significantly higher maximum drug concentration( )(median 16 v 9.5 microg/mL, P =. 0084) and area under the concentration-time curve (median 36 v 23 microg-h/mL, P =.0019) values on day 5.",Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561328/),[μg-h] / [ml],23,143618,DB00851,Dacarbazine
>,27926532,water solubility,"Notably, MPH displayed high water solubility (> 35 mg/ml) and potent PARP1/2 inhibition in a substrate-competitive manner.","Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27926532/),[mg] / [ml],35,145965,DB00851,Dacarbazine
,27926532,bioavailability,Its high bioavailability (40%~100%) and high tissue distribution in both monkeys and rats were its most important pharmacokinetic features.,"Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27926532/),%,40,145966,DB00851,Dacarbazine
,27926532,bioavailability,Its high bioavailability (40%~100%) and high tissue distribution in both monkeys and rats were its most important pharmacokinetic features.,"Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27926532/),%,100,145967,DB00851,Dacarbazine
,15173079,Oral clearance,"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),[l] / [h],10,151402,DB00851,Dacarbazine
,15173079,volume of distribution (V(D)),"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),l,30.3,151403,DB00851,Dacarbazine
,15173079,absorption constant rate,"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),1/[h],5.8,151404,DB00851,Dacarbazine
,15173079,elimination half-time,"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),h,2.1,151405,DB00851,Dacarbazine
,15173079,transfer rate from plasma to CSF (K(plasma-->CSF)),"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),1/[h],7.2 x 10(-4),151406,DB00851,Dacarbazine
,15173079,backwards rate,"Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1).",Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),1/[h],0.76,151407,DB00851,Dacarbazine
,15173079,AUC(CSF)/AUC,The AUC(CSF)/AUC(plasma) ratio was 20%.,Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173079/),%,20,151408,DB00851,Dacarbazine
,29074633,T1,"Dynamic contrast-enhanced pharmacokinetic parameters, including the volume transfer constant, the rate transfer constant, the blood plasma volume per unit volume, and the extravascular extracellular space per unit volume, were calculated by using both the fixed T1 of 1000 ms and measured T1 by using the multiple flip-angle method.",Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29074633/),m,1000,152154,DB00851,Dacarbazine
,29982805,objective response rate,"The objective response rate was 14.3%, the 6-month progression-free survival rate was 25.2%, and the 6-month overall survival rate was 69.1%.","Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29982805/),%,14.3,152282,DB00851,Dacarbazine
,29982805,progression-free survival rate,"The objective response rate was 14.3%, the 6-month progression-free survival rate was 25.2%, and the 6-month overall survival rate was 69.1%.","Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29982805/),%,25.2,152283,DB00851,Dacarbazine
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,1.1,153589,DB00851,Dacarbazine
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,2.1,153590,DB00851,Dacarbazine
,24867782,brain/plasma ratios,"Our results show that TMZ, CPT-11 and SN-38 are transported by ABCB1 at the BBB level with brain/plasma ratios of 1.1, 2.1 and 2.3, respectively.",Irinotecan and temozolomide brain distribution: a focus on ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867782/),,2.3,153591,DB00851,Dacarbazine
,10576660,bioavailability,"Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers.",Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10576660/),%,100,157681,DB00851,Dacarbazine
,10576660,MTD,"The DLT was thrombocytopenia, and the MTD was 200 mg m(-2) day(-1).",Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10576660/),mg,200,157682,DB00851,Dacarbazine
,10576660,Tmax,Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1.8 h).,Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10576660/),h,1,157683,DB00851,Dacarbazine
,10576660,t1/2,Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1.8 h).,Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10576660/),h,1.8,157684,DB00851,Dacarbazine
,18794549,apparent erlotinib clearance,The median apparent erlotinib clearance was 3.1 L/h/m(2) and the median terminal half-life was 8.7 hours.,Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794549/),[h·l] / [m(2],3.1,159978,DB00851,Dacarbazine
,18794549,terminal half-life,The median apparent erlotinib clearance was 3.1 L/h/m(2) and the median terminal half-life was 8.7 hours.,Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794549/),h,8.7,159979,DB00851,Dacarbazine
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.98,164651,DB00851,Dacarbazine
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.76,164652,DB00851,Dacarbazine
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.68,164653,DB00851,Dacarbazine
,25260842,Cmax,"Patients received escalating doses of tasisulam (3 + 3 schema; target Cmax 300-400 μg/mL) every 28 days plus 1,000 mg/m(2) gemcitabine HCl (days 1 and 15), 60 mg/m(2) docetaxel, 200 mg/m(2)/day temozolomide, 75 mg/m(2) cisplatin, or 150 mg/day erlotinib.","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[μg] / [ml],300-400,170080,DB00851,Dacarbazine
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"3,500",170081,DB00851,Dacarbazine
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"4,000",170082,DB00851,Dacarbazine
,26884555,MTD,"The MTD for alisertib was 60 mg/m(2), with mandatory myeloid growth factor support and cephalosporin prophylaxis for diarrhea.",Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),[mg] / [m],60,174301,DB00851,Dacarbazine
,26884555,overall response rate,"The overall response rate was 31.8%, with a 50% response rate observed at the MTD.",Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),%,31.8,174302,DB00851,Dacarbazine
,26884555,Progression-free survival rate,Progression-free survival rate at 2 years was 52.4%.,Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26884555/),%,52.4,174303,DB00851,Dacarbazine
,23172636,overall survival (OS),The median overall survival (OS) was 12.4 months; the 1-year OS rate was 56%.,Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23172636/),month,12.4,175244,DB00851,Dacarbazine
,21750555,PFS,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),month,1.8,178505,DB00851,Dacarbazine
,21750555,PFS,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),month,2.5,178506,DB00851,Dacarbazine
,21750555,PFS,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),month,1.4,178507,DB00851,Dacarbazine
,21750555,ORR,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),,10,178508,DB00851,Dacarbazine
,21750555,ORR,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),,3,178509,DB00851,Dacarbazine
,21750555,ORR,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),,6,178510,DB00851,Dacarbazine
,21750555,ORR,"In the dacarbazine+placebo, dacarbazine+intetumumab, 10 mg kg(-1) intetumumab, and 5 mg kg(-1) intetumumab groups, median PFS was 1.8, 2.5, 1.4, and 1.4 months; median OS was 8, 11, 15, and 9.8 months; and ORR of complete+partial response was 10, 3, 6, and 0%.","A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750555/),,0,178511,DB00851,Dacarbazine
,16639492,time to progression,"Median time to progression was 24 weeks (95% CI=16, 56), and the progression-free survival (PFS) rate was 48% at 6 months (95% CI=35%, 65%), which surpassed the protocol objective of 40%.","Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16639492/),weeks,24,179212,DB00851,Dacarbazine
,10623706,survival time,"In the intent-to-treat population, median survival time was 7.7 months for patients treated with temozolomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.52).",Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623706/),month,7.7,181638,DB00851,Dacarbazine
,10623706,survival time,"In the intent-to-treat population, median survival time was 7.7 months for patients treated with temozolomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.52).",Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623706/),month,6.4,181639,DB00851,Dacarbazine
,10623706,PFS time,"Median PFS time was significantly longer in the temozolomide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P =.012; hazards ratio, 1.37; 95% CI, 1.07 to 1.75).",Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623706/),month,1.9,181640,DB00851,Dacarbazine
,10623706,PFS time,"Median PFS time was significantly longer in the temozolomide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P =.012; hazards ratio, 1.37; 95% CI, 1.07 to 1.75).",Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623706/),month,1.5,181641,DB00851,Dacarbazine
,3664486,half-life,"The half-life of CCRG 81045 at 37 degrees C in 0.2 M phosphate buffer (pH 7.4) was 1.24 h, whereas that of 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide at 25 degrees C was reported to be 8 min (F. H. Shealy and C. A. Krauth, J. Med. Chem., 9:34-37, 1966).","Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),h,1.24,190279,DB00851,Dacarbazine
,3664486,half-life,"The half-life of CCRG 81045 at 37 degrees C in 0.2 M phosphate buffer (pH 7.4) was 1.24 h, whereas that of 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide at 25 degrees C was reported to be 8 min (F. H. Shealy and C. A. Krauth, J. Med. Chem., 9:34-37, 1966).","Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),min,8,190280,DB00851,Dacarbazine
,3664486,half-life,The half-life of CCRG 81045 in human plasma in vitro at 37 degrees C was 0.42 h.,"Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),h,0.42,190281,DB00851,Dacarbazine
,3664486,elimination half-lives,"Pharmacokinetic experiments conducted in BALB/c mice produced plasma profiles of CCRG 81045, administered i.p. or p.o., which showed a rapid absorption phase, elimination half-lives of 1.13 h (i.p.) and 1.29 h (p.o.), and a bioavailability of 0.98.","Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),h,1.13,190282,DB00851,Dacarbazine
,3664486,elimination half-lives,"Pharmacokinetic experiments conducted in BALB/c mice produced plasma profiles of CCRG 81045, administered i.p. or p.o., which showed a rapid absorption phase, elimination half-lives of 1.13 h (i.p.) and 1.29 h (p.o.), and a bioavailability of 0.98.","Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),h,1.29,190283,DB00851,Dacarbazine
,3664486,bioavailability,"Pharmacokinetic experiments conducted in BALB/c mice produced plasma profiles of CCRG 81045, administered i.p. or p.o., which showed a rapid absorption phase, elimination half-lives of 1.13 h (i.p.) and 1.29 h (p.o.), and a bioavailability of 0.98.","Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664486/),,0.98,190284,DB00851,Dacarbazine
,27503200,complete response (CR) rate,The complete response (CR) rate was 17% (8/48 patients).,A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27503200/),%,17,190820,DB00851,Dacarbazine
,12675312,peak CSF temozolomide concentration,The mean peak CSF temozolomide concentration was 26 +/- 4 microM at 2.5 h.,Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),μM,26,195003,DB00851,Dacarbazine
,12675312,areas under the temozolomide concentration-time curves,"The mean areas under the temozolomide concentration-time curves in plasma and CSF were 392 +/- 18 and 126 +/- 18 microM h, respectively, and the CSF: plasma ratio was 0.33 +/- 0.06.",Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),h·μM,392,195004,DB00851,Dacarbazine
,12675312,areas under the temozolomide concentration-time curves,"The mean areas under the temozolomide concentration-time curves in plasma and CSF were 392 +/- 18 and 126 +/- 18 microM h, respectively, and the CSF: plasma ratio was 0.33 +/- 0.06.",Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),h·μM,126,195005,DB00851,Dacarbazine
,12675312,CSF: plasma ratio,"The mean areas under the temozolomide concentration-time curves in plasma and CSF were 392 +/- 18 and 126 +/- 18 microM h, respectively, and the CSF: plasma ratio was 0.33 +/- 0.06.",Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),,0.33,195006,DB00851,Dacarbazine
,12675312,Clearance,"Clearance of temozolomide was 0.116 +/- 0.004 l/kg/h, and the volume of distribution at steady state was 0.254 +/- 0.033 l/kg.",Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),[l] / [h·kg],0.116,195007,DB00851,Dacarbazine
,12675312,volume of distribution at steady state,"Clearance of temozolomide was 0.116 +/- 0.004 l/kg/h, and the volume of distribution at steady state was 0.254 +/- 0.033 l/kg.",Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12675312/),[l] / [kg],0.254,195008,DB00851,Dacarbazine
,8262729,marrow requiring dose,The marrow requiring dose was 2000 mg/m2 when given as a single intravenous (i.v.) infusion.,A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8262729/),[mg] / [m2],2000,196868,DB00851,Dacarbazine
,8262729,terminal half-life,"At 4394 mg/m2 of DTIC, plasma concentrations declined biexponentially with a terminal half-life of 3 hours.",A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8262729/),h,3,196869,DB00851,Dacarbazine
,8262729,clearance,The mean clearance was 10.6 L/hr/m2 with a volume of distribution at steady state of 37.5 L/m2 and a mean maximum plasma concentration of 150 mcg/ml.,A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8262729/),[l] / [h·m2],10.6,196870,DB00851,Dacarbazine
,8262729,volume of distribution at steady state,The mean clearance was 10.6 L/hr/m2 with a volume of distribution at steady state of 37.5 L/m2 and a mean maximum plasma concentration of 150 mcg/ml.,A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8262729/),[l] / [m2],37.5,196871,DB00851,Dacarbazine
,8262729,maximum plasma concentration,The mean clearance was 10.6 L/hr/m2 with a volume of distribution at steady state of 37.5 L/m2 and a mean maximum plasma concentration of 150 mcg/ml.,A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8262729/),[mcg] / [ml],150,196872,DB00851,Dacarbazine
,21850464,MTDs,"The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively.",A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850464/),[mg] / [m(2],1.3,197125,DB00851,Dacarbazine
,21850464,MTDs,"The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively.",A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850464/),[mg] / [m(2],200,197126,DB00851,Dacarbazine
,14740784,time to maximum concentration,"Temozolomide was absorbed rapidly (mean time to maximum concentration 1.4 hrs) and eliminated, with average half-life and apparent oral systemic clearance values of 1.8 hours and 97 ml/minute/m2, respectively.",Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740784/),h,1.4,202550,DB00851,Dacarbazine
,14740784,half-life,"Temozolomide was absorbed rapidly (mean time to maximum concentration 1.4 hrs) and eliminated, with average half-life and apparent oral systemic clearance values of 1.8 hours and 97 ml/minute/m2, respectively.",Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740784/),h,1.8,202551,DB00851,Dacarbazine
,14740784,apparent oral systemic clearance,"Temozolomide was absorbed rapidly (mean time to maximum concentration 1.4 hrs) and eliminated, with average half-life and apparent oral systemic clearance values of 1.8 hours and 97 ml/minute/m2, respectively.",Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740784/),[ml] / [m2·min],97,202552,DB00851,Dacarbazine
,7500872,half-life,The half-life of the drug in the tumors was approximately 60 min.,Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7500872/),min,60,204377,DB00851,Dacarbazine
,27661966,entrapment efficiency,"The optimized formulation (TMZ-NLCopt) showed an entrapment efficiency of 81.64 ± 3.71%, zeta potential of 15.21 ± 3.11 mV, and polydispersity index of less than 0.2.",Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661966/),%,81.64,204987,DB00851,Dacarbazine
,27661966,zeta potential,"The optimized formulation (TMZ-NLCopt) showed an entrapment efficiency of 81.64 ± 3.71%, zeta potential of 15.21 ± 3.11 mV, and polydispersity index of less than 0.2.",Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661966/),mv,15.21,204988,DB00851,Dacarbazine
less,27661966,polydispersity index,"The optimized formulation (TMZ-NLCopt) showed an entrapment efficiency of 81.64 ± 3.71%, zeta potential of 15.21 ± 3.11 mV, and polydispersity index of less than 0.2.",Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661966/),,0.2,204989,DB00851,Dacarbazine
,22743337,flow rate,"The derivatized MX and IS were extracted by methyl-tert-butyl ether, and separated isocratically on a Xterra C18 column (2.1 mm × 100 mm) using an aqueous mobile phase containing 45% acetonitrile and 0.4% formic acid at a flow rate of 0.200 ml/min.",Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743337/),[ml] / [min],0.200,208212,DB00851,Dacarbazine
,26503473,Overall objective response rate,"Overall objective response rate was 18.8% (6 patients), all partial response; (DL1, n = 1; DL3, n = 5).",Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26503473/),%,18.8,208439,DB00851,Dacarbazine
,11212905,time to progression,Median time to progression was 3 months.,A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212905/),month,3,210160,DB00851,Dacarbazine
,11212905,AUC,"Mean AUC for DTIC, HMMTIC (5-[3-hydroxymethyl-3-methyl-1-triazeno] imidazole-4-carboxamide), and MTIC (5-[3-methyl-1-triazenol imidazole-4-carboxamide), in Arm A were 14.8, 0.17, and 1.15 mM min, respectively.",A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212905/),mM·min,14.8,210161,DB00851,Dacarbazine
,11212905,AUC,"Mean AUC for DTIC, HMMTIC (5-[3-hydroxymethyl-3-methyl-1-triazeno] imidazole-4-carboxamide), and MTIC (5-[3-methyl-1-triazenol imidazole-4-carboxamide), in Arm A were 14.8, 0.17, and 1.15 mM min, respectively.",A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212905/),mM·min,0.17,210162,DB00851,Dacarbazine
,11212905,AUC,"Mean AUC for DTIC, HMMTIC (5-[3-hydroxymethyl-3-methyl-1-triazeno] imidazole-4-carboxamide), and MTIC (5-[3-methyl-1-triazenol imidazole-4-carboxamide), in Arm A were 14.8, 0.17, and 1.15 mM min, respectively.",A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212905/),mM·min,1.15,210163,DB00851,Dacarbazine
,19001146,clearance,"Studies also showed that tremelimumab has a low clearance (0.132 ml/h x kg), a small volume of distribution (81.2 ml/kg), and a long terminal-phase half-life (22.1 days).","Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19001146/),[ml] / [h·kg],0.132,210465,DB00851,Dacarbazine
,19001146,volume of distribution,"Studies also showed that tremelimumab has a low clearance (0.132 ml/h x kg), a small volume of distribution (81.2 ml/kg), and a long terminal-phase half-life (22.1 days).","Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19001146/),[ml] / [kg],81.2,210466,DB00851,Dacarbazine
,19001146,terminal-phase half-life,"Studies also showed that tremelimumab has a low clearance (0.132 ml/h x kg), a small volume of distribution (81.2 ml/kg), and a long terminal-phase half-life (22.1 days).","Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19001146/),d,22.1,210467,DB00851,Dacarbazine
,18178958,overall response rate,"In all, 116 patients were assessable for response: 2 (1.7%) had a complete response and 19 (16.4%) a partial response (overall response rate 18.1%).",Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),%,18.1,210574,DB00851,Dacarbazine
,18178958,Overall survival,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,9.4,210575,DB00851,Dacarbazine
,18178958,PFS,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,2.8,210576,DB00851,Dacarbazine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],80,211163,DB00851,Dacarbazine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],100,211164,DB00851,Dacarbazine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],150,211165,DB00851,Dacarbazine
,15014015,MTD,"These effects were more prominent in patients receiving Seq T-->B, resulting in a much lower MTD of 80/100 mg/m(2)/day compared with 150/110 mg/m(2)/day for Seq B-->T.","A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014015/),[mg] / [d·m(2)],110,211166,DB00851,Dacarbazine
,28497258,urinary recovery,"The urinary recovery of veliparib dose as the unchanged parent compound alone and together with the M8 metabolite was 73 ± 18 and 90 ± 22%, respectively, over a 12-h dosing interval on day 6 of Cycle 1.",Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497258/),%,73,214154,DB00851,Dacarbazine
,28497258,urinary recovery,"The urinary recovery of veliparib dose as the unchanged parent compound alone and together with the M8 metabolite was 73 ± 18 and 90 ± 22%, respectively, over a 12-h dosing interval on day 6 of Cycle 1.",Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497258/),%,90,214155,DB00851,Dacarbazine
at,28497258,oral bioavailability,"Veliparib is a Biopharmaceutical Classification System (BCS) Class 1 compound, with no less than 90% of the dose absorbed and an oral bioavailability of at least 73%.",Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497258/),%,73,214156,DB00851,Dacarbazine
,16736150,Response rate,"Response rate in 23 patients was 4% (95% CI: 0-24%), and in 8 of 11 patients stable disease lasted > 6 months.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,4,214233,DB00851,Dacarbazine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,48,214234,DB00851,Dacarbazine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,28,214235,DB00851,Dacarbazine
,16736150,overall survival,"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),weeks,37,214236,DB00851,Dacarbazine
,19047122,inhibition,"Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%).","Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19047122/),%,92,218690,DB00851,Dacarbazine
,9744506,maximum-tolerated dose (MTD),"Therefore, the maximum-tolerated dose (MTD) was 1000 mg m(-2) per cycle.",Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744506/),mg,1000,219341,DB00851,Dacarbazine
,32140889,overall survival,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),month,18.2,224125,DB00851,Dacarbazine
,32140889,overall survival,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),month,17.9,224126,DB00851,Dacarbazine
,32140889,progression-free survival,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),month,7.6,224127,DB00851,Dacarbazine
,32140889,progression-free survival,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),month,11.5,224128,DB00851,Dacarbazine
,32140889,disease control rate,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),%,80,224129,DB00851,Dacarbazine
,32140889,disease control rate,"In the Phase 2a study, efficacy results for patients treated with galunisertib plus TMZ/RTX or TMZ/RTX were: median overall survival (18.2 vs 17.9 months), median progression-free survival (7.6 vs 11.5 months), and disease control rate (80% [32/40] vs 56% [9/16] patients) respectively.","Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32140889/),%,56,224130,DB00851,Dacarbazine
,15370964,Penetration,Penetration into the brain following oral or intravenous administration was 35-39% based on the brain/plasma AUC ratio.,Disposition and pharmacokinetics of temozolomide in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370964/),%,35-39,236298,DB00851,Dacarbazine
,15370964,Biliary excretion,Biliary excretion was minimal (1.4-1.6%).,Disposition and pharmacokinetics of temozolomide in rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370964/),%,1.4-1.6,236299,DB00851,Dacarbazine
,15370964,absolute oral availability,The absolute oral availability was 96-100%.,Disposition and pharmacokinetics of temozolomide in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370964/),%,96-100,236300,DB00851,Dacarbazine
,15370964,t(1/2),Temozolomide was rapidly eliminated (t(1/2) = 1.2 h) and converted to MTIC.,Disposition and pharmacokinetics of temozolomide in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370964/),h,1.2,236301,DB00851,Dacarbazine
,8431367,area under the plasma concentration vs time curve (AUC),The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes.,"Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431367/),mM·min,142,236853,DB00851,Dacarbazine
,8431367,AUC,Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites.,"Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431367/),mM·min,8,236854,DB00851,Dacarbazine
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239223,DB00851,Dacarbazine
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239224,DB00851,Dacarbazine
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239225,DB00851,Dacarbazine
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239226,DB00851,Dacarbazine
,29177975,Progression-free survival,"Progression-free survival was similar in patients with grade 3-4 hepatotoxicity (n = 109) versus grade 0-2 hepatotoxicity (n = 231) (median [95% CI]: 4.63 [4.01, 5.85] months versus 3.55 [2.73, 4.63] months; P = 0.545, HR = 0.91 [0.68-1.23]).",Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29177975/),month,4,239633,DB00851,Dacarbazine
,29177975,Progression-free survival,"Progression-free survival was similar in patients with grade 3-4 hepatotoxicity (n = 109) versus grade 0-2 hepatotoxicity (n = 231) (median [95% CI]: 4.63 [4.01, 5.85] months versus 3.55 [2.73, 4.63] months; P = 0.545, HR = 0.91 [0.68-1.23]).",Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29177975/),month,3,239634,DB00851,Dacarbazine
,11145236,clearance,"The population mean clearance for GBM or AA patients was 11.2 L/hr for male with BSA equal to 2.0 m2, and 8.8 L/hr for female with BSA equal to 1.7 m2.",Population pharmacokinetics of temozolomide in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145236/),[l] / [h],11.2,240037,DB00851,Dacarbazine
,11145236,clearance,"The population mean clearance for GBM or AA patients was 11.2 L/hr for male with BSA equal to 2.0 m2, and 8.8 L/hr for female with BSA equal to 1.7 m2.",Population pharmacokinetics of temozolomide in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145236/),[l] / [h],8.8,240038,DB00851,Dacarbazine
,26235333,MTD,We determined the MTD of TPI 287 alone and in combination with temozolomide to be 125 mg/m(2).,A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26235333/),[mg] / [m(2],125,242639,DB00851,Dacarbazine
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.71,244792,DB00851,Dacarbazine
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],4.32,244793,DB00851,Dacarbazine
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.95,244794,DB00851,Dacarbazine
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],6.51,244795,DB00851,Dacarbazine
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],118.30,244796,DB00851,Dacarbazine
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],82.11,244797,DB00851,Dacarbazine
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],245.54,244798,DB00851,Dacarbazine
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],86.62,244799,DB00851,Dacarbazine
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],346.69,244800,DB00851,Dacarbazine
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],2499.44,244801,DB00851,Dacarbazine
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],45.90,244802,DB00851,Dacarbazine
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],5800.05,244803,DB00851,Dacarbazine
,9815788,times to nadir,"The median times to nadir and recovery were 17 and 15 days, respectively.",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),d,17,248444,DB00851,Dacarbazine
,9815788,times to nadir,"The median times to nadir and recovery were 17 and 15 days, respectively.",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),d,15,248445,DB00851,Dacarbazine
,9815788,recovery,"The median times to nadir and recovery were 17 and 15 days, respectively.",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),d,15,248446,DB00851,Dacarbazine
,9815788,time to peak concentration,"Pharmacokinetic studies showed rapid absorption with a mean time to peak concentration of 60 min and mean t1/2 of 109 min (range, 80-121 min).",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),min,60,248447,DB00851,Dacarbazine
,9815788,t1/2,"Pharmacokinetic studies showed rapid absorption with a mean time to peak concentration of 60 min and mean t1/2 of 109 min (range, 80-121 min).",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),min,109,248448,DB00851,Dacarbazine
,9815788,apparent oral clearances,"The mean apparent oral clearances on day 1 for patients with and without prior NU exposure were 102+/- 27 and 115+/- 22 ml/min/m2, respectively.",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),[ml] / [m2·min],102,248449,DB00851,Dacarbazine
,9815788,apparent oral clearances,"The mean apparent oral clearances on day 1 for patients with and without prior NU exposure were 102+/- 27 and 115+/- 22 ml/min/m2, respectively.",Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815788/),[ml] / [m2·min],115,248450,DB00851,Dacarbazine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m(2],562,249373,DB00851,Dacarbazine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m(2],407,249374,DB00851,Dacarbazine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m],472,249375,DB00851,Dacarbazine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m],355,249376,DB00851,Dacarbazine
,8616836,Total systemic clearance,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[ml] / [kg·min],39.8,254356,DB00851,Dacarbazine
,8616836,Total systemic clearance,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[ml] / [kg·min],44.2,254357,DB00851,Dacarbazine
,8616836,volume of distribution,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[l] / [kg],5.4,254358,DB00851,Dacarbazine
,8616836,volume of distribution,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[l] / [kg],5.2,254359,DB00851,Dacarbazine
,8616836,area under the interstitial fluid concentration-time curve,"However, the mean TMZ area under the interstitial fluid concentration-time curve was reduced by 25% in the TNP-470-treated group compared to the control (5450 +/- 1892 versus 4120 +/- 1790 micrograms min ml(-1); P < 0.05).",Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[min·μg] / [ml],5450,254360,DB00851,Dacarbazine
,8616836,area under the interstitial fluid concentration-time curve,"However, the mean TMZ area under the interstitial fluid concentration-time curve was reduced by 25% in the TNP-470-treated group compared to the control (5450 +/- 1892 versus 4120 +/- 1790 micrograms min ml(-1); P < 0.05).",Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[min·μg] / [ml],4120,254361,DB00851,Dacarbazine
,11302252,half-life,The half-life of temozolomide was 1.86 (+/-0.31) h.,"A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302252/),h,1.86,255049,DB00851,Dacarbazine
,26438157,brain to plasma ratio,"Consistent with the influence of these efflux pumps on central nervous system drug distribution, Mdr1a/b(-/-)Bcrp1(-/-) knockout mice had a significantly higher brain to plasma ratio for rucaparib (1.61 ± 0.25) than wild-type mice (0.11 ± 0.08).",Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26438157/),,1.61,255463,DB00851,Dacarbazine
,26438157,brain to plasma ratio,"Consistent with the influence of these efflux pumps on central nervous system drug distribution, Mdr1a/b(-/-)Bcrp1(-/-) knockout mice had a significantly higher brain to plasma ratio for rucaparib (1.61 ± 0.25) than wild-type mice (0.11 ± 0.08).",Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26438157/),,0.11,255464,DB00851,Dacarbazine
,19171709,area under the plasma concentration versus time curve,The median SN-38 lactone area under the plasma concentration versus time curve at this dose was 72 ng . hr/mL.,Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19171709/),[h·ng] / [ml],72,256758,DB00851,Dacarbazine
,17971589,clearance,"The mean clearance of temozolomide was 107 mL/min/m2, with a volume of distribution of 20 L/m2 and half-life of 109 minutes.",Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971589/),[ml] / [m2·min],107,259380,DB00851,Dacarbazine
,17971589,volume of distribution,"The mean clearance of temozolomide was 107 mL/min/m2, with a volume of distribution of 20 L/m2 and half-life of 109 minutes.",Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971589/),[l] / [m2],20,259381,DB00851,Dacarbazine
,17971589,half-life,"The mean clearance of temozolomide was 107 mL/min/m2, with a volume of distribution of 20 L/m2 and half-life of 109 minutes.",Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971589/),min,109,259382,DB00851,Dacarbazine
,29077941,M,The MTD was set at 1.5 mg/kg in arm B and was not reached in arm C. RP2D was declared as 1.25 mg/kg for both arms.,"Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077941/),[mg] / [kg],1.5,260118,DB00851,Dacarbazine
,29077941,progression-free survival (PFS) rate,"In recurrent glioblastoma patients, the progression-free survival (PFS) rate at 6 months was 30.8% and the median overall survival was 10.7 months.","Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077941/),%,30.8,260119,DB00851,Dacarbazine
,29077941,overall survival,"In recurrent glioblastoma patients, the progression-free survival (PFS) rate at 6 months was 30.8% and the median overall survival was 10.7 months.","Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077941/),month,10.7,260120,DB00851,Dacarbazine
,17694310,maximum dose,The starting dose of temozolomide was 150 mg/m(2)/day for 5 days every 28 days and could be escalated to a maximum dose of 200 mg/m(2)/day in subsequent cycles.,Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [m],200,260762,DB00851,Dacarbazine
,17694310,MTD,"For patients on EIAEDs, the MTD of gefitinib was 1,000 mg/day in combination with temozolomide.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [d],"1,000",260763,DB00851,Dacarbazine
,17694310,MTD,"For patients not on EIAEDs, the MTD was 250 mg/day in combination with temozolomide.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [d],250,260764,DB00851,Dacarbazine
,17694310,terminal half-life,"The peak concentration and AUC(0-24hr) at the 500 mg dose level was 1.8 and 2.5-fold lower, respectively, in the EIAED group compared to the non-EIAED group; trough levels of gefitinib increased in both groups consistent with the reported terminal half-life ranging from 27 to 51 h.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),h,27 to 51,260765,DB00851,Dacarbazine
,19430790,T (max),"Temozolomide was rapidly absorbed (mean T (max), 2.1 h).",Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19430790/),h,2.1,261133,DB00851,Dacarbazine
,19430790,apparent clearance (CL/F),The mean apparent clearance (CL/F) (96 mL/min/m(2)) was similar to the CL/F for temozolomide alone and was not age- or gender-dependent.,Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19430790/),[min·ml] / [m(2],96,261134,DB00851,Dacarbazine
,29294212,half-life (t1/2),The in vivo pharmacokinetic parameters proved sustained release fashion such as half-life (t1/2) of 22.74 h (PCT) rather than15.35 h (TMZ) only.,Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29294212/),h,22.74,264558,DB00851,Dacarbazine
,29294212,half-life (t1/2),The in vivo pharmacokinetic parameters proved sustained release fashion such as half-life (t1/2) of 22.74 h (PCT) rather than15.35 h (TMZ) only.,Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29294212/),h,15.35,264559,DB00851,Dacarbazine
,10501912,time to maximum plasma concentration (t(max)),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.8,267114,DB00851,Dacarbazine
,10501912,elimination half-life (t(1/2)),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.8,267115,DB00851,Dacarbazine
,10501912,t(max),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.9,267116,DB00851,Dacarbazine
,10501912,t(1/2),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.9,267117,DB00851,Dacarbazine
,23285701,method,The method recovery of TMZ from human plasma was consistent and ranged 37.1-41.1%.,Validated HPLC method for determination of temozolomide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23285701/),%,37.1-41.1,272947,DB00851,Dacarbazine
,23285701,recovery,The method recovery of TMZ from human plasma was consistent and ranged 37.1-41.1%.,Validated HPLC method for determination of temozolomide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23285701/),%,37.1-41.1,272948,DB00851,Dacarbazine
